Preparation, characterization and biocompatibility studies on risperidone-loaded solid lipid nanoparticles (SLN): High pressure homogenization versus ultrasound

Colloids and Surfaces B: Biointerfaces

Volumn 86, Issue 1, 2011, Pages 158-165

  Silva, A C ^a,b   Gonzalez Mira E ^c   Garcia M L ^c   Egea, M A ^c   Fonseca, J ^a   Silva, R ^a   Santos, D ^a   Souto, E B ^b,d   Ferreira, D ^a  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSIDADE FERNANDO PESSOA   (Portugal)

^c UNIVERSITY OF BARCELONA   (Spain)

^d UNIVERSITY OF TRÁS OS MONTES AND ALTO DOURO   (Portugal)

Author keywords

Biocompatibility; High pressure homogenization; Oral delivery; Risperidone; Solid lipid nanoparticles; Ultrasound

Indexed keywords

HIGH PRESSURE HOMOGENIZATION; ORAL DELIVERY; RISPERIDONE; SOLID LIPID NANOPARTICLES; ULTRASOUND;

ASSAYS; BIOCOMPATIBILITY; BROMINE COMPOUNDS; DIFFERENTIAL SCANNING CALORIMETRY; DISPERSIONS; PRODUCTION; ULTRASONIC APPLICATIONS; ULTRASONICS; ZETA POTENTIAL;

NANOPARTICLES;

RISPERIDONE; SOLID LIPID NANOPARTICLE;

ARTICLE; CELL STRAIN CACO 2; CELL VIABILITY; COLLOID; CONTROLLED STUDY; CYTOTOXICITY; DIFFERENTIAL SCANNING CALORIMETRY; DISPERSION; DRUG FORMULATION; DRUG MANUFACTURE; ENCAPSULATION; HIGH PRESSURE HOMOGENIZATION; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; ULTRASOUND; X RAY; ZETA POTENTIAL;

CALORIMETRY; LIPIDS; NANOPARTICLES; PARTICLE SIZE; RISPERIDONE;

EID: 79955794727     PISSN: 09277765     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.colsurfb.2011.03.035     Document Type: Article

References (38)

1. Müller R.H., Mehnert W., Lucks J.S., Schwarz C., zur Muhlen A., Weyhers H., Freitas C., Ruhl D. Solid lipid nanoparticles (SLN)-an alternative colloidal carrier system for controlled drug delivery. Eur. J. Pharm. Biopharm. 1995, 41:62-69.
2. Müller R.H., Mader K., Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art. Eur. J. Pharm. Biopharm. 2000, 50:161-177.
3. M.R. Gasco, Method for producing solid lipid microspheres having a narrow size distribution, United States of America Patent, 1993.
4. Sarmento B., Martins S., Ferreira D., Souto E.B. Oral insulin delivery by means of solid lipid nanoparticles. Int. J. Nanomed. 2007, 2:743-749.
5. Kristl J., Volk B., Ahlin P., Gombac K., Sentjurc M. Interactions of solid lipid nanoparticles with model membranes and leukocytes studied by EPR. Int. J. Pharm. 2003, 256:133-140.
6. Gokce E.H., Sandri G., Bonferoni M.C., Rossi S., Ferrari F., Guneri T., Caramella C. Cyclosporineo A loaded SLNs: evaluation of cellular uptake and corneal cytotoxicity. Int. J. Pharm. 2008, 364:76-86.
7. Wang Y., Deng Y., Mao S., Jin S., Wang J., Bi D. Characterization and body distribution of beta-elemene solid lipid nanoparticles (SLN). Drug Dev. Ind. Pharm. 2005, 31:769-778.
8. Zhang N., Ping Q., Huang G., Xu W., Cheng Y., Han X. Lectin-modified solid lipid nanoparticles as carriers for oral administration of insulin. Int. J. Pharm. 2006, 327:153-159.
9. Liu K., Sun J., Wang Y., He Y., Gao K., He Z. Preparation and characterization of 10-hydroxycamptothecin loaded nanostructured lipid carriers. Drug Dev. Ind. Pharm. 2008, 34:465-471.
10. Mehnert W., Mader K. Solid lipid nanoparticles: production, characterization and applications. Adv. Drug Deliv. Rev. 2001, 47:165-196.
11. Wissing S.A, Kayser O., Müller R.H. Solid lipid nanoparticles for parenteral drug delivery. Adv. Drug Deliv. Rev. 2004, 56:1257-1272.
12. Bhanji N.H., Chouinard G., Margolese H.C. A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia. Eur. Neuropsychopharmacol. 2004, 14:87-92.
13. Chue P, Welch R., Binder C. Acceptability and disintegration rates of orally disintegrating risperidone tablets in patients with schizophrenia or schizoaffective disorder. Can. J. Psychiatry 2004, 49:701-703.
14. Lindenberg M., Kopp S., Dressman J.B. Classification of orally administered drugs on the World Health Organization model list of essential medicines according to the biopharmaceutics classification system. Eur. J. Pharm. Biopharm. 2004, 58:265-278.
15. Porter C.J., Pouton C.W., Cuine J.F., Charman W.N. Enhancing intestinal drug solubilisation using lipid-based delivery systems. Adv. Drug Deliv. Rev. 2008, 60:673-691.
16. Patil M.N., Pandit A.B. Cavitation-a novel technique for making stable nano-suspensions. Ultrason. Sonochem. 2007, 14:519-530.
17. Freitas C., Müller R.H. Correlation between long-term stability of solid lipid nanoparticles (SLN) and crystallinity of the lipid phase. Eur. J. Pharm. Biopharm. 1999, 47:125-132.
18. Celia C., Trapasso E., Cosco D., Paolino D., Fresta M. Turbiscan lab expert analysis of the stability of ethosomes and ultradeformable liposomes containing a bilayer fluidizing agent. Colloids Surf. B: Biointerfaces 2009, 72:155-160.
19. Mengual O., Meunier G., Cayre I., Puech K., Snabre P. TURBISCAN MA 2000: multiple light scattering measurement for concentrated emulsion and suspension instability analysis. Talanta 1999, 50:445-456.
20. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 1983, 65:55-63.
21. Meunier V., Bourrie M., Berger Y., Fabre G. The human intestinal epithelial cell line Caco-2; pharmacological and pharmacokinetic applications. Cell Biol. Toxicol. 1995, 11:187-194.
22. Grant S., Fitton A. Risperidone. A review of its pharmacology and therapeutic potential in the treatment of schizophrenia. Drugs 1994, 48:253-273.
23. Müller R.H., Runge S., Ravelli V., Mehnert W., Thunemann A.F., Souto E.B. Oral bioavailability of cyclosporine: solid lipid nanoparticles (SLN) versus drug nanocrystals. Int. J. Pharm. 2006, 317:82-89.
24. Müller R.H., Runge S.A., Ravelli V., Thunemann A.F., Mehnert W., Souto E.B. Cyclosporine-loaded solid lipid nanoparticles (SLN): drug-lipid physicochemical interactions and characterization of drug incorporation. Eur. J. Pharm. Biopharm. 2008, 68:535-544.
25. 1H NMR. Pharmazie 2005, 60:508-513.
26. Souto E.B., Anselmi C., Centini M., Müller R.H. Preparation and characterization of n-dodecyl-ferulate-loaded solid lipid nanoparticles (SLN). Int. J. Pharm. 2005, 295:261-268.
27. Bhaskar K., Anbu J., Ravichandiran V., Venkateswarlu V., Rao Y.M. Lipid nanoparticles for transdermal delivery of flurbiprofen: formulation, in vitro, ex vivo and in vivo studies. Lipids Health Dis. 2009, 8:6.
28. Hatziantoniou S, Deli G., Nikas Y., Demetzos C., Papaioannou G.T. Scanning electron microscopy study on nanoemulsions and solid lipid nanoparticles containing high amounts of ceramides. Micron 2007, 38:819-823.
29. Rahman Z., Zidan A.S., Khan M.A. Non-destructive methods of characterization of risperidone solid lipid nanoparticles. Eur. J. Pharm. Biopharm. 2010, 76:127-137.
30. Luo Y., Chen D., Ren L., Zhao X., Qin J. Solid lipid nanoparticles for enhancing vinpocetine's oral bioavailability. J. Control. Release 2006, 114:53-59.
31. Bunjes H., Unruh T. Characterization of lipid nanoparticles by differential scanning calorimetry, X-ray and neutron scattering. Adv. Drug Deliv. Rev. 2007, 59:379-402.
32. Gonzalez-Mira E., Egea M.A., Garcia M.L., Souto E.B. Design and ocular tolerance of flurbiprofen loaded ultrasound-engineered NLC. Colloids Surf. B: Biointerfaces 2010, 81:412-421.
33. Bunjes H., Steiniger F., Richter W. Visualizing the structure of triglyceride nanoparticles in different crystal modifications. Langmuir 2007, 23:4005-4011.
34. Müller R.H., Ruhl D., Runge S., Schulze-Forster K., Mehnert W. Cytotoxicity of solid lipid nanoparticles as a function of the lipid matrix and the surfactant. Pharm. Res. 1997, 14:458-462.
35. Nassimi M., Schleh C., Lauenstein H.D., Hussein R., Hoymann H.G., Koch W., Pohlmann G., Krug N., Sewald K., Rittinghausen S., Braun A., Muller-Goymann C. A toxicological evaluation of inhaled solid lipid nanoparticles used as a potential drug delivery system for the lung. Eur. J. Pharm. Biopharm. 2010, 75:107-116.
36. Müller R.H., Maassen S., Weyhers H., Mehnert W. Phagocytic uptake and cytotoxicity of solid lipid nanoparticles (SLN) sterically stabilized with poloxamine 908 and poloxamer 407. J. Drug Target. 1996, 4:161-170.
37. Rouxhet L., Dinguizli M., Latere Dwan'isa J.P., Ould-Ouali L., Twaddle P., Nathan A., Brewster M.E., Rosenblatt J., Arien A., Preat V. Monoglyceride-based self-assembling copolymers as carriers for poorly water-soluble drugs. Int. J. Pharm. 2009, 382:244-253.
38. Müller R.H., Maassen S., Weyhers H., Specht F., Lucks J.S. Cytotoxicity of magnetite-loaded polylactide, polylactide/glycolide particles and solid lipid nanoparticles. Int. J. Pharm. 1996, 138:85-94.